Statera BioPharma (FRA:7CB) Total Receivables: €0.37 Mil (As of Sep. 2022)


FRA:7CB Statera BioPharma Inc FRA:7CB
20 GF Score
Price €2.61
View Full Analysis

What is Statera BioPharma Total Receivables?

Statera BioPharma FRA:7CB 20 Total Receivables is €0.37 Mil as of Sep. 2022. GuruFocus rates FRA:7CB with a GF Score™ of 20/100.

Statera BioPharma's Total Receivables for the quarter that ended in Sep. 2022 was €0.37 Mil.

Statera BioPharma Total Receivables Related Terms

Statera BioPharma Total Receivables Historical Data

* Premium members only.

The historical data trend for Statera BioPharma's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Statera BioPharma Total Receivables Chart

Statera BioPharma Annual Data
Trend Dec19 Dec20 Dec21
Total Receivables
0.00 0.27 0.31

Statera BioPharma Quarterly Data
Dec19 Mar20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.12 0.31 0.26 0.39 0.37
FRA:7CB
20GF Score
Statera BioPharma Inc FRA:7CB
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Statera BioPharma Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.37 Mil mean?
Statera BioPharma (FRA:7CB) has a Total Receivables of €0.37 Mil as of Sep. 2022. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Statera BioPharma and its competitors.
Is Statera BioPharma's Total Receivables too high?
Statera BioPharma's current Total Receivables is €0.37 Mil. Overall, Statera BioPharma has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Statera BioPharma's Total Receivables compare to NRBO and PALI?
Statera BioPharma's Total Receivables of €0.37 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Statera BioPharma and its competitors. Statera BioPharma's current Total Receivables is €0.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Statera BioPharma stock overvalued right now?
Statera BioPharma (FRA:7CB) has a current Total Receivables of €0.37 Mil. The current Total Receivables is €0.37 Mil. Statera BioPharma's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Statera BioPharma (FRA:7CB), the current Total Receivables is €0.37 Mil as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Statera BioPharma Business Description

Address 2580 East Harmony Road, Suite 316, Fort Collins, CO, USA, 80528
Statera BioPharma Inc is a pre-clinical and clinical biopharmaceutical company developing multiple product candidates to address unmet medical needs for use in diseases involving immune system dysfunction. Its proprietary platform of Toll-like receptor drug candidates has applications in mitigation of radiation injury, mitigation of T-cell exhaustion, inflammation, T-cell exhaustion, immune system dysfunction, oncology, infection and neutropenia.
20GF Score

Get the complete analysis for FRA:7CB

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.61
Price